These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
411 related articles for article (PubMed ID: 21896911)
21. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Patterson KB; Prince HA; Kraft E; Jenkins AJ; Shaheen NJ; Rooney JF; Cohen MS; Kashuba AD Sci Transl Med; 2011 Dec; 3(112):112re4. PubMed ID: 22158861 [TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection. Kiser JJ; Fletcher CV; Flynn PM; Cunningham CK; Wilson CM; Kapogiannis BG; Major-Wilson H; Viani RM; Liu NX; Muenz LR; Harris DR; Havens PL; Antimicrob Agents Chemother; 2008 Feb; 52(2):631-7. PubMed ID: 18025112 [TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137. Ramanathan S; Shen G; Cheng A; Kearney BP J Acquir Immune Defic Syndr; 2007 Jul; 45(3):274-9. PubMed ID: 17414929 [TBL] [Abstract][Full Text] [Related]
24. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis. Pozniak AL; Gallant JE; DeJesus E; Arribas JR; Gazzard B; Campo RE; Chen SS; McColl D; Enejosa J; Toole JJ; Cheng AK J Acquir Immune Defic Syndr; 2006 Dec; 43(5):535-40. PubMed ID: 17057609 [TBL] [Abstract][Full Text] [Related]
25. Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. Castillo-Mancilla JR; Zheng JH; Rower JE; Meditz A; Gardner EM; Predhomme J; Fernandez C; Langness J; Kiser JJ; Bushman LR; Anderson PL AIDS Res Hum Retroviruses; 2013 Feb; 29(2):384-90. PubMed ID: 22935078 [TBL] [Abstract][Full Text] [Related]
26. A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results. Zolopa A; Sax PE; DeJesus E; Mills A; Cohen C; Wohl D; Gallant JE; Liu HC; Plummer A; White KL; Cheng AK; Rhee MS; Szwarcberg J; J Acquir Immune Defic Syndr; 2013 May; 63(1):96-100. PubMed ID: 23392460 [TBL] [Abstract][Full Text] [Related]
27. Tenofovir and emtricitabine concentrations in hair are comparable between individuals on tenofovir disoproxil fumarate versus tenofovir alafenamide-based ART. Okochi H; Louie A; Phung N; Zhang K; Tallerico RM; Kuncze K; Spinelli MA; Koss CA; Benet LZ; Gandhi M Drug Test Anal; 2021 Jul; 13(7):1354-1370. PubMed ID: 33742745 [TBL] [Abstract][Full Text] [Related]
28. Concomitant administration of BILR 355/r with emtricitabine/tenofovir disoproxil fumarate increases exposure to emtricitabine and tenofovir: a randomized, open-label, prospective study. Huang F; Scholl P; Huang DB; MacGregor TR; Taub ME; Vinisko R; Castles MA; Robinson P Basic Clin Pharmacol Toxicol; 2011 Mar; 108(3):163-70. PubMed ID: 20977679 [TBL] [Abstract][Full Text] [Related]
29. Liver and renal safety of tenofovir disoproxil fumarate in combination with emtricitabine among African women in a pre-exposure prophylaxis trial. Mandala J; Nanda K; Wang M; De Baetselier I; Deese J; Lombaard J; Owino F; Malahleha M; Manongi R; Taylor D; Van Damme L BMC Pharmacol Toxicol; 2014 Dec; 15():77. PubMed ID: 25539648 [TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV. German P; Warren D; West S; Hui J; Kearney BP J Acquir Immune Defic Syndr; 2010 Nov; 55(3):323-9. PubMed ID: 20683270 [TBL] [Abstract][Full Text] [Related]
31. Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and prevention. Jackson A; Moyle G; Watson V; Tjia J; Ammara A; Back D; Mohabeer M; Gazzard B; Boffito M J Acquir Immune Defic Syndr; 2013 Mar; 62(3):275-81. PubMed ID: 23274933 [TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic and safety analyses of tenofovir and tenofovir-emtricitabine vaginal tablets in pigtailed macaques. Pereira LE; Clark MR; Friend DR; Garber DA; McNicholl JM; Hendry RM; Doncel GF; Smith JM Antimicrob Agents Chemother; 2014 May; 58(5):2665-74. PubMed ID: 24566178 [TBL] [Abstract][Full Text] [Related]
33. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. DeJesus E; Rockstroh JK; Henry K; Molina JM; Gathe J; Ramanathan S; Wei X; Yale K; Szwarcberg J; White K; Cheng AK; Kearney BP; Lancet; 2012 Jun; 379(9835):2429-2438. PubMed ID: 22748590 [TBL] [Abstract][Full Text] [Related]
34. Safety, efficacy, and persistence of emtricitabine/tenofovir versus other nucleoside analogues in naive subjects aged 50 years or older in Spain: the TRIP study. Blanco JR; Caro-Murillo AM; Castaño MA; Olalla J; Domingo P; Arazo P; Gómez-Sirvent JL; Riera M; Pulido F; Vera F; Romero-Palacios A; Aguirrebengoa K; Portilla J; Ferrer P; Pedrol E HIV Clin Trials; 2013; 14(5):204-15. PubMed ID: 24144897 [TBL] [Abstract][Full Text] [Related]
35. Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine? Foster C; Lyall H; Olmscheid B; Pearce G; Zhang S; Gibb DM HIV Med; 2009 Aug; 10(7):397-406. PubMed ID: 19459986 [TBL] [Abstract][Full Text] [Related]
36. Pregnancy-related effects on tenofovir pharmacokinetics: a population study with 186 women. Benaboud S; Hirt D; Launay O; Pannier E; Firtion G; Rey E; Bouazza N; Foissac F; Chappuy H; Urien S; Tréluyer JM Antimicrob Agents Chemother; 2012 Feb; 56(2):857-62. PubMed ID: 22123690 [TBL] [Abstract][Full Text] [Related]
37. Atazanavir pharmacokinetics with and without tenofovir during pregnancy. Mirochnick M; Best BM; Stek AM; Capparelli EV; Hu C; Burchett SK; Rossi SS; Hawkins E; Basar M; Smith E; Read JS; J Acquir Immune Defic Syndr; 2011 Apr; 56(5):412-9. PubMed ID: 21283017 [TBL] [Abstract][Full Text] [Related]
38. Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study. Semvua HH; Mtabho CM; Fillekes Q; van den Boogaard J; Kisonga RM; Mleoh L; Ndaro A; Kisanga ER; van der Ven A; Aarnoutse RE; Kibiki GS; Boeree MJ; Burger DM Antivir Ther; 2013; 18(1):105-13. PubMed ID: 23043067 [TBL] [Abstract][Full Text] [Related]
39. Early upper digestive tract side effects of zidovudine with tenofovir plus emtricitabine in West African adults with high CD4 counts. Ouattara E; Danel C; Moh R; Gabillard D; Peytavin G; Konan R; Carrou JL; Bohoussou F; Eholie SP; Anglaret X J Int AIDS Soc; 2013 Apr; 16(1):18059. PubMed ID: 23639243 [TBL] [Abstract][Full Text] [Related]
40. Steady-state amprenavir, tenofovir, and emtricitabine pharmacokinetics before and after reducing ritonavir boosting of a fosamprenavir/tenofovir/emtricitabine regimen from 200 mg to 100 mg once daily (TELEX II). Parks DA; Jennings HC; Taylor C; Pakes GE; Acosta EP HIV Clin Trials; 2009; 10(3):160-7. PubMed ID: 19632955 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]